Literature DB >> 30393613

Targeting IL22: a potential therapeutic approach for Kras mutant lung cancer?

Frank D Weinberg1, Nithya Ramnath1.   

Abstract

Entities:  

Year:  2018        PMID： 30393613      PMCID： PMC6193907          DOI： 10.21037/tlcr.2018.09.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  25 in total

1.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

Review 2.  Biological and pathological activities of interleukin-22.

Authors:  Mirna Perusina Lanfranca; Yanwei Lin; Jingyuan Fang; Weiping Zou; Timothy Frankel
Journal:  J Mol Med (Berl)       Date:  2016-02-29       Impact factor: 4.599

3.  Interleukin-22 promotes lung cancer cell proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways.

Authors:  Yi Bi; Jingyan Cao; Shi Jin; Liyan Lv; Li Qi; Fang Liu; Jianxiong Geng; Yan Yu
Journal:  Mol Cell Biochem       Date:  2016-03-17       Impact factor: 3.396

4.  In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression.

Authors:  Ogyi Park; Hua Wang; Honglei Weng; Lionel Feigenbaum; Hai Li; Shi Yin; Sung Hwan Ki; Seong Ho Yoo; Steven Dooley; Fu-Sheng Wang; Howard A Young; Bin Gao
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

5.  Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells.

Authors:  Sebastian Kobold; Stefanie Völk; Till Clauditz; Natascha Jennifer Küpper; Sarah Minner; Amanda Tufman; Peter Düwell; Michael Lindner; Ina Koch; Simon Heidegger; Simon Rothenfuer; Max Schnurr; Rudolf Maria Huber; Waldemar Wilczak; Stefan Endres
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

6.  IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties.

Authors:  Nasim Khosravi; Mauricio S Caetano; Amber M Cumpian; Nese Unver; Cynthia De la Garza Ramos; Oscar Noble; Soudabeh Daliri; Belinda J Hernandez; Berenice A Gutierrez; Scott E Evans; Samir Hanash; Andrei M Alekseev; Yi Yang; Seon Hee Chang; Roza Nurieva; Humam Kadara; Jichao Chen; Edwin J Ostrin; Seyed Javad Moghaddam
Journal:  Cancer Immunol Res       Date:  2018-05-15       Impact factor: 11.151

7.  Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model.

Authors:  Seyed Javad Moghaddam; Huaiguang Li; Sung-Nam Cho; Megan K Dishop; Ignacio I Wistuba; Lin Ji; Jonathan M Kurie; Burton F Dickey; Francesco J Demayo
Journal:  Am J Respir Cell Mol Biol       Date:  2008-10-16       Impact factor: 6.914

8.  Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10.

Authors:  Diane Lejeune; Laure Dumoutier; Stefan Constantinescu; Wiebe Kruijer; Jan Jacob Schuringa; Jean-Christophe Renauld
Journal:  J Biol Chem       Date:  2002-06-26       Impact factor: 5.157

9.  High fat diet induces formation of spontaneous liposarcoma in mouse adipose tissue with overexpression of interleukin 22.

Authors:  Zheng Wang; Ling Yang; Yuhui Jiang; Zhi-Qiang Ling; Zhigang Li; Yuan Cheng; Heng Huang; Lingdi Wang; Yi Pan; Zhenzhen Wang; Xiaoqiang Yan; Yan Chen
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

10.  MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer.

Authors:  Yanli He; Lihui Wang; Weijun Liu; Jinjie Zhong; Shengbin Bai; Zhuwen Wang; Dafydd G Thomas; Jules Lin; Rishindra M Reddy; Nithya Ramnath; Philip W Carrott; William R Lynch; Mark B Orringer; Andrew C Chang; David G Beer; Guoan Chen
Journal:  Sci Rep       Date:  2015-06-19       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.